Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

nd the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of FavId and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations, including the conditions to the Company's ability to access the committed equity financing facility and therefore fund operations through the first half of 2008; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

FAVRILLE, INC.

(a development stage company)

BALANCE SHEETS

(in thousands, except share and per share data)

September December


'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
(Date:1/14/2014)... Critical Care, a LifeCentre partner practice, located at 165 Fort Evans ... in Loudoun County to receive a small ... Barnes , Medical Director, is a well-seasoned veterinarian of more than ... are avid scuba divers. "As altitude skiers and hikers, we recognize ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... WOONSOCKET, R.I. , July 30 MultiCell Technologies, Inc. ... fresh new look and updated information about discovery technology platforms and ... common questions. , , ... "The new website is designed to inform our shareholders, scientists and ...
... July 29 As of late, the most prominently ... Lap-Band procedure, a minimally invasive operation in which an adjustable ... in order to restrict food capacity and promote weight loss. ... Lap Band surgery without the use of the band ...
Cached Medicine Technology:MultiCell Technologies Launches New Web Site 2MultiCell Technologies Launches New Web Site 3Sleeve Gastrectomy Procedure With Dr. Michael Feiz Serves as a Highly Effective Alternative to Lap Band Surgery 2Sleeve Gastrectomy Procedure With Dr. Michael Feiz Serves as a Highly Effective Alternative to Lap Band Surgery 3
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease ... neurons may be mistaken for foreign invaders and killed ... way autoimmune diseases like type I diabetes, celiac disease, ... was published April 16, 2014, in Nature Communications ... idea in Parkinson,s disease; but if true, it could ...
(Date:4/17/2014)... led by researchers at UC Davis has shown that ... role in cell division, also boosts the mitochondrial activity ... the complex has been shown to perform both jobs. ... target to control cellular energy production, potentially advancing cancer ... today in the journal Developmental Cell . , ...
(Date:4/17/2014)... 2014 Meaningful long-term survival is possible for ... abdomen when treated with cytoreductive surgery with Hyperthermic ... analysis by physicians at Wake Forest Baptist Medical ... reported, single-center experience with cytoreductive surgery and HIPEC, ... analysis of 20 years, worth of patient data ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... rates far below goals, study finds , , TUESDAY, Nov. ... asthma and other high-risk illnesses are getting flu shots, ... from 1992 to 2002 for 18,703 adolescents with asthma, ... During the study period, vaccination rates improved, but only ...
... Patients and Physicians -, ADDISON, Texas, Nov. ... announced that it has launched a new Altrazeal(TM) ... professionals and patients on,the clinical benefits of Altrazeal(TM)., ... the use of,Altrazeal(TM) and product attributes and benefits, ...
... ASN, EL SEGUNDO, Calif., Nov. 4 ... for those diagnosed with chronic kidney,disease (CKD), in ... abstracts to the 41st Annual Meeting &,Scientific Exposition ... developed both internally and through intellectual,partnerships with leaders ...
... XOMA Ltd. (Nasdaq:,XOMA), a leader in the discovery and ... a conference call and webcast on,Monday, November 10 at ... results and provide a general business update., The ... quarter 2008,financial results earlier that morning. The webcast can ...
... Quantum Group,Inc. (Amex: QGP ), a Wellington, ... Guillama, President & Chief Executive Officer,will be presenting ... 12, 2008. Mr. Guillama will be joined by ... Innovations Officer,and Ron Smith, Senior Vice President Corporate ...
... Nov. 4 /PRNewswire-FirstCall/ - Haemacure Corporation,(TSX:HAE) announced today ... Haemacure, will present at the Rodman and Renshaw ... New York. Mr. Galli will,present a corporate progress ... candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure,presentation is scheduled ...
Cached Medicine News:Health News:Too Many High-Risk Teens Not Getting Flu Shots 2Health News:ULURU Inc. Announces the Launch of the Altrazeal(TM) Website 2Health News:ULURU Inc. Announces the Launch of the Altrazeal(TM) Website 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 2Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 3Health News:DaVita Abstracts Accepted into American Society of Nephrology Meeting 4Health News:XOMA to Announce Third Quarter 2008 Financial Results and Host Conference Call on November 10 2Health News:XOMA to Announce Third Quarter 2008 Financial Results and Host Conference Call on November 10 3Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 2Health News:The Quantum Group Inc. To Present at Paulson Investment's 31st Annual Westergaard Conference 3Health News:Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference 2
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Adjustable piston accommodates 7 - 9 mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9 mm trephine blades and 18 mm diameter Teflon block. Designed for accurate ...
... Surgical Markers have a unique squeezable ... for writing over wet prep solutions. ... Markers with optional rulers and sterile ... provided sterile, packaged individually in peel ...
Medicine Products: